Genprex (GNPX) Gets a Buy Rating from Noble Financial

Noble Financial analyst Cosme Ordonez reiterated a Buy rating on Genprex (GNPX) today and set a price target of $5.00. The company’s shares closed last Friday at $2.75.

Ordonez has an average return of 27.5% when recommending Genprex.

According to, Ordonez is ranked #2735 out of 6619 analysts.

Genprex has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.03 and a one-year low of $0.23. Currently, Genprex has an average volume of 3.17M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts